Bio-Rad Laboratories Inc (NYSE:BIO) Share Price

Company Profile

Business description
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Contact
1000 Alfred Nobel Drive
HerculesCA94547
USA
T: +1 510 724-7000
E: [email protected]
https://www.bio-rad.com
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
8,030

Recommended

Shares drop 17% after guidance is revised but we still see value.

Shane Ponraj | 09 January 2025

Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.

Joseph Taylor | 09 January 2025

These undervalued stocks with reliable dividends are worth considering.

Susan Dziubinski | 08 January 2025

Index	Last price	Change	% Change
All Ordinaries	8,543.70	34.10	-0.40%
CAC 40	7,431.04	59.24	-0.79%
DAX 40	20,214.79	102.31	-0.50%
Dow JONES (US)	41,938.45	696.75	-1.63%
FTSE 100	8,248.49	71.20	-0.86%
HKSE	19,064.29	176.60	-0.92%
NASDAQ	19,161.63	317.25	-1.63%
Nikkei 225	39,190.40	414.69	-1.05%
NZX 50 Index	12,895.98	47.76	-0.37%
S&P 500	5,827.04	91.21	-1.54%
S&P/ASX 200	8,294.10	35.10	-0.42%
SSE Composite Index	3,168.52	42.87	-1.33%